[
  {
    "date": "2023-12-30",
    "symbol": "EVOK",
    "period": "FY",
    "netincomeloss": -7792295,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Evoke Pharma, Inc.",
    "entitycentralindexkey": 1403708,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "security12btitle": "Common Stock, par value $0.0001 per share",
    "tradingsymbol": "EVOK",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-36075",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "20-8447886",
    "entityaddressaddressline1": "420 Stevens Avenue",
    "entityaddressaddressline2": "Suite 230",
    "entityaddresscityortown": "Solana Beach",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 92075,
    "cityareacode": 858,
    "localphonenumber": "345-1494",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "auditorfirmid": 243,
    "auditorname": "BDO USA, P.C.",
    "auditorlocation": "San Diego, California",
    "cashandcashequivalentsatcarryingvalue": 4739426,
    "receivablesnetcurrent": 673071,
    "prepaidexpensecurrent": 885040,
    "inventorynet": 481840,
    "otherassetscurrent": 47532,
    "assetscurrent": 6826909,
    "deferredcosts": 241637,
    "assets": 7068546,
    "accountspayableandaccruedliabilitiescurrent": 1711778,
    "employeerelatedliabilitiescurrent": 1324010,
    "liabilitiescurrent": 3035788,
    "longtermnotespayable": 5000000,
    "accountspayableandaccruedliabilitiesnoncurrent": 1612295,
    "liabilitiesnoncurrent": 6612295,
    "liabilities": 9648083,
    "commonstockvalue": 334,
    "additionalpaidincapitalcommonstock": 120859567,
    "retainedearningsaccumulateddeficit": -123439438,
    "stockholdersequity": -2579537,
    "liabilitiesandstockholdersequity": 7068546,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 5000000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 50000000,
    "commonstocksharesissued": 3343070,
    "commonstocksharesoutstanding": 3343070,
    "revenuefromcontractwithcustomerexcludingassessedtax": 5180630,
    "costofgoodssoldexpenses": 201879,
    "typeofcostgoodorserviceextensiblelist": "http://fasb.org/us-gaap/2023#ProductMember",
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 181907,
    "sellinggeneralandadministrativeexpense": 12227735,
    "operatingexpenses": 12611521,
    "operatingincomeloss": -7430891,
    "interestincomeexpensenonoperatingnet": 138596,
    "interestexpense": 500000,
    "nonoperatingincomeexpense": -361404,
    "earningspersharebasic": -2.33,
    "earningspersharediluted": -2.33,
    "weightedaveragenumberofsharesoutstandingbasic": 3343070,
    "weightedaveragenumberofdilutedsharesoutstanding": 3343070,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 1128109,
    "noncashleaseexpense": 129074,
    "sharebasedcompensation": 1128109,
    "increasedecreaseinaccountsreceivable": 48239,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -31932,
    "increasedecreaseininventories": 192462,
    "increasedecreaseinotheraccountspayableandaccruedliabilities": 655126,
    "accruedcompensation": -732852,
    "increasedecreaseinaccruedinterestpayable": 500000,
    "increasedecreaseinoperatingleaseliability": -129074,
    "netcashprovidedbyusedinoperatingactivities": -4984977,
    "paymentsofstockissuancecosts": 119296,
    "netcashprovidedbyusedinfinancingactivities": -119296,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -5104273,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 4739426,
    "publicofferingcostsincludedinaccountspayableandaccruedexpenses": 122340,
    "entityincorporationmonthandyearofincorporation": "2007-01",
    "debtinstrumentfaceamount": 6600000,
    "principalandinterestonloandueperiod": "P90D",
    "numberofoperatingsegments": 1,
    "inventoryrawmaterials": 361000,
    "inventoryfinishedgoods": 121000,
    "medicaidandmedicarerebates": 46000,
    "liabilitiesforcopayassistance": 66000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 624232,
    "leasecommencementdate": "2017-01-01",
    "lesseeoperatingleaseexistenceofoptiontoextend": "true",
    "leaseexpirationdate1": "2023-10-31",
    "operatingleaseincrementalborrowingrate": 0.1,
    "operatingleaseexpense": 154000,
    "operatingleasepayments": 146000,
    "lesseeoperatingleaseremainingleaseterm": "P0Y9M29D",
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 63000,
    "descriptionofmaterialcontingenciesofparentcompany": "upon the initiation of the first patient dosing in the Company’s Phase 3 clinical trial for Gimoti",
    "milestonepaymentscontingentamount": 52000000,
    "numberofmilestonepayments": 1,
    "paymentsforroyalties": 134000,
    "commonstockvotingrights": "Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.",
    "commonstockcapitalsharesreservedforfutureissuance": 1317451,
    "sharebasedcompensationarrangementbysharebasedpaymentawardtermsofaward": "In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 2,500 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 547838,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardrequisiteserviceperiod1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P1Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 153750,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsoutstandingdateintrinsicvalue": 1.05,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 2.42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 624232,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 21369,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 624232,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 418591,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 14.25,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 3.07,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 45.78,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 14.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 14.64,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P7Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2granted": "P9Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P7Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P6Y2M23D",
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 1100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P0Y9M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorizedforemployeestockpurchaseplan": 145381,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0134,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.9934,
    "minimumageofemployeetoparticipateindefinedbenefitplan": "P21Y",
    "definedcontributionplanemployerdiscretionarycontributionamount": 3000,
    "unreimbursedcommercializationcost": 63500000,
    "lineofcreditfacilitydescription": "On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.",
    "unrecognizedtaxbenefits": 2000000,
    "incometaxexaminationyearunderexamination": 2007,
    "deferredtaxassetsoperatinglosscarryforwards": 25800000,
    "cumulativeminimumchangeinownershippercentageforlimitationonutilizationofnetoperatinglosscarryforwards": 0.5,
    "cumulativechangeinownershipperiod": "P3Y",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 3600000,
    "valuationallowancedeferredtaxassetchangeinamount": 208000,
    "operatinglosscarryforwards": 105800000,
    "operatinglosscarryforwardsexpirationdate": "2027-12-31",
    "deferredtaxassetsoperatinglosscarryforwardsnotsubjecttoexpiration": 43900000,
    "taxcreditcarryforwardamount": 2400000,
    "percentageoftaxableincomeoffsetbytaxlosses": 0.8,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.03,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.01,
    "effectiveincometaxratereconciliationoperatinglossandtaxcreditsother": 0.16,
    "effectiveincometaxratereconciliationchangeinenactedtaxrate": -0.01,
    "effectiveincometaxratereconciliationdeductibleexpensesharebasedcompensationandotherpermanentitems": 0.02,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1839000,
    "deferredtaxassetsinprocessresearchanddevelopment": 161000,
    "deferredtaxassetstaxaccrualsandother": 294000,
    "deferredtaxassetsgross": 2294000,
    "deferredtaxassetsvaluationallowance": 2294000
  },
  {
    "date": "2022-12-30",
    "symbol": "EVOK",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2022 ",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Evoke Pharma, Inc.",
    "entitycentralindexkey": 1403708,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "security12btitle": "Common Stock, par value $0.0001 per share",
    "tradingsymbol": "EVOK",
    "securityexchangename": "Nasdaq",
    "entityfilenumber": "001-36075",
    "entityincorporationstatecountrycode": "Delaware",
    "entitytaxidentificationnumber": "20-8447886",
    "entityaddressaddressline1": "420 Stevens Avenue",
    "entityaddressaddressline2": "Suite 370",
    "entityaddresscityortown": "Solana Beach",
    "entityaddressstateorprovince": "California",
    "entityaddresspostalzipcode": 92075,
    "cityareacode": 858,
    "localphonenumber": "345-1494",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "auditorfirmid": 243,
    "auditorname": "BDO USA, LLP",
    "auditorlocation": "San Diego, California",
    "cashandcashequivalentsatcarryingvalue": "null",
    "receivablesnetcurrent": 624832,
    "prepaidexpensecurrent": 952954,
    "inventorynet": 289378,
    "otherassetscurrent": 11551,
    "assetscurrent": "null",
    "operatingleaserightofuseasset": 129074,
    "assets": "null",
    "accountspayableandaccruedliabilitiescurrent": 934312,
    "employeerelatedliabilitiescurrent": 591158,
    "operatingleaseliabilitycurrent": 129074,
    "liabilitiescurrent": "null",
    "longtermnotespayable": "null",
    "accountspayableandaccruedliabilitiesnoncurrent": "null",
    "liabilitiesnoncurrent": "null",
    "liabilities": "null",
    "commonstockvalue": 334,
    "additionalpaidincapitalcommonstock": "null",
    "retainedearningsaccumulateddeficit": "-null",
    "stockholdersequity": "-null",
    "liabilitiesandstockholdersequity": "null",
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": "null",
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": 621697,
    "commonstocksharesoutstanding": "null",
    "revenuefromcontractwithcustomerexcludingassessedtax": "null",
    "costofgoodssoldexpenses": 370394,
    "typeofcostgoodorserviceextensiblelist": "http://fasb.org/us-gaap/2022#ProductMember",
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 300789,
    "sellinggeneralandadministrativeexpense": 2000000,
    "operatingexpenses": "null",
    "operatingincomeloss": "-null",
    "interestincomeexpensenonoperatingnet": 62007,
    "interestexpense": 500000,
    "nonoperatingincomeexpense": -437993,
    "netincomeloss": "-null",
    "earningspersharebasic": -2.62,
    "earningspersharediluted": -2.62,
    "weightedaveragenumberofsharesoutstandingbasic": "null",
    "weightedaveragenumberofdilutedsharesoutstanding": "null",
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": "null",
    "issuanceofcommonstockfromatthemarketofferingsvalue": "null",
    "issuanceofcommonstockfromatthemarketofferingsshares": 621697,
    "paymentofatmarketofferingcosts": 148993,
    "noncashleaseexpense": 37025,
    "sharebasedcompensation": "null",
    "increasedecreaseinaccountsreceivable": 329639,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 29208,
    "increasedecreaseininventories": 103843,
    "increasedecreaseinaccountspayableandothercurrentliabilities": 60284,
    "accruedcompensation": -71840,
    "accruedinterestexpense": 500000,
    "increasedecreaseinoperatingleaseliability": -37025,
    "netcashprovidedbyusedinoperatingactivities": "-null",
    "proceedsfromissuanceofcommonstockatmarketoffering": 7300000,
    "netcashprovidedbyusedinfinancingactivities": "null",
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 698989,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": "null",
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 153671,
    "entityincorporationmonthandyearofincorporation": "January 2007",
    "numberofoperatingsegments": 1,
    "inventoryrawmaterials": 239000,
    "inventoryfinishedgoods": 50000,
    "liabilitiesforcopayassistance": 66000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 491851,
    "leasecommencementdate": "January 1, 2017",
    "lesseeoperatingleaseexistenceofoptiontoextend": "extend",
    "leaseexpirationdate1": "October 31, 2023",
    "operatingleaseincrementalborrowingrate": 0.1,
    "shorttermleaseexpense": 112000,
    "operatingleaseexpense": 38000,
    "operatingleasepayments": 39000,
    "lesseeoperatingleaseremainingleaseterm": 0.83,
    "descriptionofmaterialcontingenciesofparentcompany": "depended on Gimoti’s commercial success. The Company was required to pay Mallinckrodt a low single digit royalty percentage on net sales of Gimoti",
    "milestonepaymentscontingentamount": 47000000,
    "numberofmilestonepayments": 1,
    "paymentsforroyalties": 134000,
    "commonstockvotingrights": " Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company. ",
    "commonstockweightedaveragepricepershare": 11.97,
    "classofwarrantorrightnumberofsecuritiesexpired": 139972,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 34.8,
    "commonstockcapitalsharesreservedforfutureissuance": 675396,
    "sharebasedcompensationarrangementbysharebasedpaymentawardtermsofaward": "In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 2,500 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 146497,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardrequisiteserviceperiod1": " ten-year",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "four year ",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 78247,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsoutstandingdateintrinsicvalue": 2.68,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 4.86,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 491851,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 4184,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 491851,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 327107,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 19.11,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 6.1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 20.72,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 19.11,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 20.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 7.22,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2granted": 9.24,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2expiredorforfeitedorexchanged": 7.42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": 7.22,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 6.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 9440,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 9440,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 1180,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 1800000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorizedforemployeestockpurchaseplan": 37048,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0355,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 6,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.1323,
    "minimumageofemployeetoparticipateindefinedbenefitplan": 21,
    "unreimbursedcommercializationcost": 48400000,
    "lineofcreditfacilitydescription": "On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.",
    "unrecognizedtaxbenefits": 2000000,
    "incometaxexaminationyearunderexamination": 2007,
    "deferredtaxassetsoperatinglosscarryforwards": 24500000,
    "cumulativeminimumchangeinownershippercentageforlimitationonutilizationofnetoperatinglosscarryforwards": 0.5,
    "cumulativechangeinownershipperiod": "three-year ",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 3600000,
    "valuationallowancedeferredtaxassetchangeinamount": 20000,
    "operatinglosscarryforwards": 52100000,
    "operatinglosscarryforwardsexpirationdate": "2028-12-31",
    "deferredtaxassetsoperatinglosscarryforwardsnotsubjecttoexpiration": 38200000,
    "taxcreditcarryforwardamount": 1500000,
    "percentageoftaxableincomeoffsetbytaxlosses": 0.8,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.02,
    "effectiveincometaxratereconciliationoperatinglossandtaxcreditsother": 0.24,
    "effectiveincometaxratereconciliationchangeinenactedtaxrate": 0.01,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": "null",
    "deferredtaxassetsinprocessresearchanddevelopment": 125000,
    "deferredtaxassetsleaseliability": 29000,
    "deferredtaxassetstaxaccrualsandother": 136000,
    "deferredtaxassetsgross": "null",
    "deferredtaxliabilitiesrightofuseasset": 29000,
    "deferredincometaxliabilities": 29000,
    "deferredtaxassetsvaluationallowance": "null"
  },
  {
    "date": "2021-12-30",
    "symbol": "EVOK",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Evoke Pharma Inc",
    "entitycentralindexkey": 1403708,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "security12btitle": "Common Stock, par value $0.0001 per share",
    "tradingsymbol": "EVOK",
    "securityexchangename": "Nasdaq",
    "entityfilenumber": "001-36075",
    "entityincorporationstatecountrycode": "Delaware",
    "entitytaxidentificationnumber": "20-8447886",
    "entityaddressaddressline1": "420 Stevens Avenue",
    "entityaddressaddressline2": "Suite 370",
    "entityaddresscityortown": "Solana Beach",
    "entityaddressstateorprovince": "California",
    "entityaddresspostalzipcode": 92075,
    "cityareacode": 858,
    "localphonenumber": "345-1494",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "auditorfirmid": 243,
    "auditorname": "BDO USA, LLP",
    "auditorlocation": "San Diego, California",
    "cashandcashequivalentsatcarryingvalue": "null",
    "receivablesnetcurrent": 295193,
    "prepaidexpensecurrent": 923746,
    "inventorynet": 185534,
    "otherassetscurrent": 11551,
    "assetscurrent": "null",
    "operatingleaserightofuseasset": 12428,
    "assets": "null",
    "accountspayableandaccruedliabilitiescurrent": 874028,
    "employeerelatedliabilitiescurrent": 519317,
    "operatingleaseliabilitycurrent": 12428,
    "liabilitiescurrent": "null",
    "longtermnotespayable": "null",
    "accountspayableandaccruedliabilitiesnoncurrent": 612295,
    "liabilitiesnoncurrent": "null",
    "liabilities": "null",
    "commonstockvalue": 3266,
    "additionalpaidincapitalcommonstock": "null",
    "retainedearningsaccumulateddeficit": "-null",
    "stockholdersequity": "-null",
    "liabilitiesandstockholdersequity": "null",
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": "null",
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": 217100,
    "commonstocksharesoutstanding": "null",
    "revenuefromcontractwithcustomerexcludingassessedtax": "null",
    "costofgoodssoldexpenses": 328118,
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 590476,
    "sellinggeneralandadministrativeexpense": 1300000,
    "operatingexpenses": "null",
    "operatingincomeloss": "-null",
    "forgivenessofpaycheckprotectionloanandaccruedinterest": 105130,
    "interestincomeexpensenonoperatingnet": 8615,
    "interestexpense": 500050,
    "nonoperatingincomeexpense": -386305,
    "netincomeloss": "-null",
    "earningspersharebasicanddiluted": -0.27,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": "null",
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": "null",
    "stockissuedduringperiodvaluenewissues": "null",
    "stockissuedduringperiodsharesnewissues": "null",
    "issuanceofcommonstockfromstockoptionexercisevalue": 45454,
    "issuanceofcommonstockfromstockoptionexerciseshares": 67426,
    "issuanceofcommonstockfromatthemarketofferingsvalue": 313107,
    "issuanceofcommonstockfromatthemarketofferingsshares": 217100,
    "paymentsofstockissuancecosts": 6421,
    "inventorywritedown": 30000,
    "forgivenessofpaycheckprotectionloanandaccruedinterest1": -105130,
    "sharebasedcompensation": "null",
    "increasedecreaseinaccountsreceivable": 271882,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -157593,
    "increasedecreaseininventories": -20946,
    "increasedecreaseinaccountspayableandothercurrentliabilities": -527859,
    "accruedcompensation": 496915,
    "accruedinterestexpense": 499301,
    "milestonepayment": "-null",
    "netcashprovidedbyusedinoperatingactivities": "-null",
    "proceedsfromissuanceofcommonstock": 313000,
    "proceedsfromissuanceofcommonstockatmarketoffering": 313107,
    "proceedsfromstockoptionsexercised": 45454,
    "netcashprovidedbyusedinfinancingactivities": "null",
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": "null",
    "loansassumed1": 105130,
    "entityincorporationmonthandyearofincorporation": "January 2007",
    "numberofoperatingsegments": 1,
    "inventoryrawmaterials": 150000,
    "inventoryfinishedgoods": 35000,
    "inventoryvaluationreserves": 30000,
    "liabilitiesforcopayassistance": 44000,
    "proceedfromsaleofresearchproduct": 718000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": "null",
    "leasecommencementdate": "January 1, 2017",
    "leaseexpirationdate1": "October 31, 2022",
    "operatingleaseincrementalborrowingrate": 0.1,
    "operatingleaserightofuseestimatedasset": 12000,
    "operatingleaserightofuseestimatedliability": 12000,
    "operatingleaseexpense": 136000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 12000,
    "descriptionofmaterialcontingenciesofparentcompany": "depend on Gimoti’s commercial success. The Company is required to pay Mallinckrodt a low single digit royalty percentage on net sales of Gimoti.",
    "milestonepaymentscontingentamount": 47000000,
    "numberofmilestonepayments": 1,
    "estimatedyearofpatentexpiration": 2030,
    "paymentsforroyalties": 51000,
    "commonstockvotingrights": "Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.",
    "commonstockweightedaveragepricepershare": 1.47,
    "classofwarrantorrightnumberofsecuritiesexpired": 162206,
    "classofwarrantorrightoutstanding": "null",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 2.9,
    "classofwarrantorrightoutstandingweightedaverageremainingcontractualterm": 0.08,
    "commonstockcapitalsharesreservedforfutureissuance": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardtermsofaward": "In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 30,000 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.",
    "additionalnumberofcommonstockcapitalsharesreservedforfutureissuance": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardrequisiteserviceperiod1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "four year",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": "null",
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsoutstandingdateintrinsicvalue": 0.55,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.93,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": "null",
    "stockissuedduringperiodsharesstockoptionsexercised": 67426,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 678374,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 1.8,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.42,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 0.67,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 2.85,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 1.8,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 1.83,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P7Y10M6D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2granted": "P9Y1M17D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2exercised": "P7Y4M20D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2expiredorforfeitedorexchanged": "P6Y6M14D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P7Y10M6D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P7Y3M7D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalueoptionsexercised": 43715,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalueoptionsexpiredorforfeitedorexchanged": 3923,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 2900000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": 1.32,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorizedforemployeestockpurchaseplan": 344574,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0013000000000000002,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 0.5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.1198000000000001,
    "minimumageofemployeetoparticipateindefinedbenefitplan": 21,
    "unreimbursedcommercializationcost": 27000000,
    "lineofcreditfacilitydescription": "On February 1, 2022, the Eversana Agreement was amended (the “Amended Eversana Agreement”) to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.",
    "unrecognizedtaxbenefits": 2000000,
    "incometaxexaminationyearunderexamination": 2007,
    "deferredtaxassetsoperatinglosscarryforwards": 22500000,
    "cumulativeminimumchangeinownershippercentageforlimitationonutilizationofnetoperatinglosscarryforwards": 0.5,
    "cumulativechangeinownershipperiod": "P3Y",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 3600000,
    "operatinglosscarryforwards": 47800000,
    "operatinglosscarryforwardsexpirationdate": "2028-12-31",
    "deferredtaxassetsoperatinglosscarryforwardsnotsubjecttoexpiration": 29400000,
    "taxcreditcarryforwardamount": 1500000,
    "percentageoftaxableincomeoffsetbytaxlosses": 0.8,
    "percentageofannualusagelimitationonnetoperatinglosscarryforward": 0.8,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.05,
    "effectiveincometaxratereconciliationoperatinglossandtaxcreditsother": 0.25,
    "effectiveincometaxratereconciliationdeductibleexpensesharebasedcompensationandotherpermanentitems": 0.01,
    "deferredtaxassetsgoodwillandintangibleassets": 543000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": "null",
    "deferredtaxassetsleaseliability": 3000,
    "deferredtaxassetstaxaccrualsandother": 110000,
    "deferredtaxassetsgross": "null",
    "deferredtaxliabilitiesrightofuseasset": 3000,
    "deferredincometaxliabilities": 3000,
    "deferredtaxassetsvaluationallowance": "null"
  },
  {
    "date": "2020-12-30",
    "symbol": "EVOK",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Evoke Pharma Inc",
    "entitycentralindexkey": 1403708,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "security12btitle": "Common Stock, par value $0.0001 per share",
    "tradingsymbol": "EVOK",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-36075",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "20-8447886",
    "entityaddressaddressline1": "420 Stevens Avenue",
    "entityaddressaddressline2": "Suite 370",
    "entityaddresscityortown": "Solana Beach",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 92075,
    "cityareacode": 858,
    "localphonenumber": "345-1494",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "cashandcashequivalentsatcarryingvalue": 8068939,
    "receivablesnetcurrent": 23311,
    "prepaidexpensecurrent": 921762,
    "inventorynet": 236480,
    "otherassetscurrent": 30300,
    "assetscurrent": 9280792,
    "operatingleaserightofuseasset": 142000,
    "otherassetsnoncurrent": 11551,
    "assets": 9434048,
    "accountspayableandaccruedliabilitiescurrent": 1273572,
    "employeerelatedliabilitiescurrent": 1016232,
    "operatingleaseliabilitycurrent": 142000,
    "paycheckprotectionprogramloan": 104168,
    "milestonepayable": 5000000,
    "liabilitiescurrent": 7535677,
    "longtermnotespayable": 5000000,
    "accountspayableandaccruedliabilitiesnoncurrent": 112994,
    "liabilitiesnoncurrent": 5112994,
    "liabilities": 12648671,
    "commonstockvalue": 2662,
    "additionalpaidincapitalcommonstock": 95667776,
    "retainedearningsaccumulateddeficit": -98885061,
    "stockholdersequity": -98885061,
    "liabilitiesandstockholdersequity": 9434048,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 5000000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 50000000,
    "commonstocksharesissued": 1490813,
    "commonstocksharesoutstanding": 26621954,
    "revenuefromcontractwithcustomerexcludingassessedtax": 23020,
    "costofgoodssoldexpenses": 86712,
    "typeofcostgoodorserviceextensiblelist": "us-gaap:ProductMember",
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 6554825,
    "sellinggeneralandadministrativeexpense": 6428832,
    "operatingexpenses": 13070369,
    "operatingincomeloss": -13047349,
    "interestincomeexpensenonoperatingnet": 5672,
    "interestexpense": 112994,
    "nonoperatingincomeexpense": -107322,
    "netincomeloss": -13154671,
    "earningspersharebasicanddiluted": -0.52,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 25492169,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 1628558,
    "stockissuedduringperiodvalueemployeestockpurchaseplan": 119416,
    "stockissuedduringperiodsharesemployeestockpurchaseplans": 118491,
    "issuanceofcommonstockfromwarrantexercisevalue": -38,
    "issuanceofcommonstockfromwarrantexerciseshares": 381625,
    "issuanceofcommonstockfromstockoptionexercisevalue": 215816,
    "issuanceofcommonstockfromstockoptionexerciseshares": 199111,
    "issuanceofcommonstockfromatthemarketofferingsvalue": 3595713,
    "issuanceofcommonstockfromatthemarketofferingsshares": 1490813,
    "paymentsofstockissuancecosts": 73939,
    "sharebasedcompensation": 1311666,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 396834,
    "increasedecreaseininventories": 236480,
    "increasedecreaseinaccountspayableandaccruedliabilities": 416426,
    "accruedinterestexpense": 112994,
    "milestonepayment": 5000000,
    "netcashprovidedbyusedinoperatingactivities": -6630007,
    "proceedsfromissuanceofcommonstock": 30000000,
    "proceedsfromissuanceofsharesunderincentiveandsharebasedcompensationplans": 119416,
    "proceedsfromstockoptionsexercised": 215816,
    "proceedsfromissuanceofunsecureddebt": 104168,
    "proceedsfromlinesofcredit": 5000000,
    "netcashprovidedbyusedinfinancingactivities": 9035113,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 2405106,
    "entityincorporationmonthandyearofincorporation": "2007-01",
    "numberofoperatingsegments": 1,
    "inventoryrawmaterials": 150000,
    "inventoryfinishedgoods": 86000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 5931380,
    "leasecommencementdate": "2017-01-01",
    "leaseexpirationdate1": "2022-01-31",
    "operatingleaseincrementalborrowingrate": 0.1,
    "leaseandrentalexpense": 151000,
    "operatingleasesfutureminimumpaymentsduecurrent": 137000,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 12000,
    "descriptionofmaterialcontingenciesofparentcompany": "depend on Gimoti’s commercial success. The Company will be required to pay Mallinckrodt a low single digit royalty on net sales of Gimoti.",
    "milestonepaymentscontingentamount": 47000000,
    "numberofmilestonepayments": 1,
    "otherloanspayable": 5000000,
    "subordinatedborrowingduedate": "2021-06-19",
    "researchanddevelopmentexpense": 5000000,
    "estimatedyearofpatentexpiration": 2030,
    "commonstockvotingrights": "Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.",
    "commonstockweightedaveragepricepershare": 2.46,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": 871682,
    "classofwarrantorrightsweightedaverageexercisepriceofwarrantsorrightsexercisable": 2.77,
    "classofwarrantorrightoutstanding": 1841879,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 2.98,
    "classofwarrantorrightoutstandingweightedaverageremainingcontractualterm": "P1Y14D",
    "commonstockcapitalsharesreservedforfutureissuance": 7566145,
    "sharebasedcompensationarrangementbysharebasedpaymentawardtermsofaward": "In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 30,000 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P4Y",
    "additionalnumberofcommonstockcapitalsharesreservedforfutureissuance": 4073526,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 1402433,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardrequisiteserviceperiod1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 1172000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsoutstandingdateintrinsicvalue": 2.58,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.23,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 4077259,
    "stockissuedduringperiodsharesstockoptionsexercised": 199111,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 10001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 4077259,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 1943106,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 1.7,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 1.58,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 1.08,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 2.42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 1.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 2.32,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y1M2D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2granted": "P9Y2M19D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2exercised": "P2Y9M10D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2expiredorforfeitedorexchanged": "P6Y11M4D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P8Y1M2D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P7Y3M25D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 5134768,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalueoptionsexercised": 484188,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalueoptionsexpiredorforfeitedorexchanged": 30620,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 5134768,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 1967591,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 2000000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P1Y1M2D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorizedforemployeestockpurchaseplan": 244574,
    "accruedpayrolltaxescurrent": 119000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0111,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.1198,
    "minimumageofemployeetoparticipateindefinedbenefitplan": "P21Y",
    "unreimbursedcommercializationcost": 9000000,
    "lineofcreditfacilitycurrentborrowingcapacity": 3000000,
    "unrecognizedtaxbenefits": 2000000,
    "incometaxexaminationyearunderexamination": 2007,
    "deferredtaxassetsoperatinglosscarryforwards": 20400000,
    "cumulativeminimumchangeinownershippercentageforlimitationonutilizationofnetoperatinglosscarryforwards": 0.5,
    "cumulativechangeinownershipperiod": "P3Y",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 3500000,
    "operatinglosscarryforwards": 47700000,
    "operatinglosscarryforwardsexpirationdate": "2028-12-31",
    "deferredtaxassetsoperatinglosscarryforwardsnotsubjecttoexpiration": 19500000,
    "taxcreditcarryforwardamount": 1500000,
    "percentageoftaxableincomeoffsetbytaxlosses": 0.8,
    "percentageofannualusagelimitationonnetoperatinglosscarryforward": 0.8,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.06,
    "effectiveincometaxratereconciliationtaxcreditsresearchanddevelopment": -0.01,
    "effectiveincometaxratereconciliationoperatinglossandtaxcreditsother": 0.11,
    "effectiveincometaxratereconciliationchangeinenactedtaxrate": -0.02,
    "effectiveincometaxratereconciliationdeductibleexpensesharebasedcompensationandotherpermanentitems": 0.01,
    "deferredtaxassetsgoodwillandintangibleassets": 1089000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 695000,
    "deferredtaxassetsleaseliability": 59000,
    "deferredtaxassetstaxaccrualsandother": 214000,
    "deferredtaxassetsgross": 2057000,
    "deferredtaxliabilitiesrightofuseasset": 59000,
    "deferredincometaxliabilities": 59000,
    "deferredtaxassetsvaluationallowance": 1998000
  },
  {
    "date": "2019-12-30",
    "symbol": "EVOK",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Evoke Pharma Inc",
    "entitycentralindexkey": 1403708,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entityshellcompany": "false",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "security12btitle": "Common Stock, par value $0.0001 per share",
    "tradingsymbol": "EVOK",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-36075",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "20-8447886",
    "entityaddressaddressline1": "420 Stevens Avenue",
    "entityaddressaddressline2": "Suite 370",
    "entityaddresscityortown": "Solana Beach",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 92075,
    "cityareacode": 858,
    "localphonenumber": "345-1494",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "cashandcashequivalentsatcarryingvalue": 5663833,
    "prepaidexpensecurrent": 581706,
    "assetscurrent": 6245539,
    "operatingleaserightofuseasset": 139000,
    "otherassetsnoncurrent": 11551,
    "assets": 6395628,
    "accountspayableandaccruedliabilitiescurrent": 1033383,
    "employeerelatedliabilitiescurrent": 843162,
    "operatingleaseliabilitycurrent": 139000,
    "liabilitiescurrent": 2015083,
    "commonstockvalue": 2443,
    "additionalpaidincapitalcommonstock": 90108492,
    "retainedearningsaccumulateddeficit": -85730390,
    "stockholdersequity": -85730390,
    "liabilitiesandstockholdersequity": 6395628,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 5000000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 50000000,
    "commonstocksharesissued": 7004381,
    "commonstocksharesoutstanding": 24431914,
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 3416466,
    "generalandadministrativeexpense": 3737987,
    "operatingexpenses": 7154453,
    "operatingincomeloss": -7154453,
    "interestincomeexpensenonoperatingnet": 28798,
    "nonoperatingincomeexpense": 28798,
    "netincomeloss": -7125655,
    "earningspersharebasicanddiluted": -0.32,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 22296089,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 1373958,
    "stockissuedduringperiodvaluenewissues": 6106922,
    "stockissuedduringperiodsharesnewissues": 7004381,
    "sharebasedcompensation": 663803,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 116676,
    "increasedecreaseinaccountspayableandaccruedliabilities": 106280,
    "netcashprovidedbyusedinoperatingactivities": -5762093,
    "proceedsfromissuanceofcommonstock": 6100000,
    "netcashprovidedbyusedinfinancingactivities": 6106922,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 344829,
    "entityincorporationmonthandyearofincorporation": "2007-01",
    "numberofoperatingsegments": 1,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 5852932,
    "leasecommencementdate": "2017-01-01",
    "leaseexpirationdate1": "2020-12-31",
    "operatingleaseincrementalborrowingrate": 0.12,
    "leaseandrentalexpense": 145000,
    "capitalleasesfutureminimumpaymentsduecurrent": 146000,
    "descriptionofmaterialcontingenciesofparentcompany": "Depend on Gimoti’s commercial success and will only apply if Gimoti receives regulatory approval.  In addition, the Company will be required to pay Mallinckrodt a low single digit royalty on net sales of Gimoti",
    "milestonepaymentscontingentamount": 47000000,
    "numberofmilestonepayments": 1,
    "estimatedyearofpatentexpiration": 2032,
    "commonstockvotingrights": "Each share of common stock is entitled to one vote.  The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.",
    "sharesofcommonstocksubjecttoregistrationrights": 1509789,
    "commonstockweightedaveragepricepershare": 0.89,
    "classofwarrantorrightoutstanding": 2713561,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 2.91,
    "classofwarrantorrightoutstandingweightedaverageremainingcontractualterm": "P2Y14D",
    "commonstockcapitalsharesreservedforfutureissuance": 7678152,
    "sharebasedcompensationarrangementbysharebasedpaymentawardtermsofaward": "In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 30,000 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.",
    "sharebasedcompensationarrangementincreaseinnumberofsharesreservedforissuancepercentageunderplan": 0.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P4Y",
    "additionalnumberofcommonstockcapitalsharesreservedforfutureissuance": 4073526,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 1587155,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardrequisiteserviceperiod1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 2672246,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsoutstandingdateintrinsicvalue": 1.62,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 3114371,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 2575499,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 3114371,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 1230605,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 1.71,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 1.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 2.82,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 1.71,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 3.17,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y3M26D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2granted": "P9Y4M9D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2expiredorforfeitedorexchanged": "P7Y5M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P8Y3M26D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P6Y8M12D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 2143756,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 2143756,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 392604,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 1883766,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 494674,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitednumberofshares": 1411213,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedweightedaveragegrantdatefairvalue": 0.75,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedweightedaveragegrantdatefairvalue": 1.53,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 2100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P1Y2M26D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorizedforemployeestockpurchaseplan": 263065,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0252,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.7068,
    "minimumageofemployeetoparticipateindefinedbenefitplan": "P21Y",
    "unrecognizedtaxbenefits": 2000000,
    "incometaxexaminationyearunderexamination": 2007,
    "deferredtaxassetsoperatinglosscarryforwards": 19000000,
    "cumulativeminimumchangeinownershippercentageforlimitationonutilizationofnetoperatinglosscarryforwards": 0.5,
    "cumulativechangeinownershipperiod": "P3Y",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 3500000,
    "operatinglosscarryforwards": 47700000,
    "operatinglosscarryforwardsexpirationdate": "2028-12-31",
    "deferredtaxassetsoperatinglosscarryforwardsnotsubjecttoexpiration": 12600000,
    "taxcreditcarryforwardamount": 1400000,
    "percentageoftaxableincomeoffsetbytaxlosses": 0.8,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.04,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.07,
    "effectiveincometaxratereconciliationtaxcreditsresearchanddevelopment": 0.03,
    "effectiveincometaxratereconciliationoperatinglossandtaxcreditsother": 0.27,
    "effectiveincometaxratereconciliationchangeinenactedtaxrate": 0.04,
    "effectiveincometaxratereconciliationdeductibleexpensesharebasedcompensationandotherpermanentitems": 0.04,
    "deferredtaxassetsgoodwillandintangibleassets": 80000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 846000,
    "deferredtaxassetsleaseliability": 39000,
    "deferredtaxassetstaxaccrualsandother": 237000,
    "deferredtaxassetsgross": 1202000,
    "deferredtaxliabilitiesrightofuseasset": 39000,
    "deferredincometaxliabilities": 39000,
    "deferredtaxassetsvaluationallowance": 1163000
  }
]